此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy

2014年12月10日 更新者:Memorial Sloan Kettering Cancer Center

Phase I Study of Selective Internal Radiation Therapy (SIRT) in Patients With Unresectable Colorectal Cancer Liver Metastases Who Failed Prior Intraarterial Pump Chemotherapy

This study is being done with a new therapy called "Selective Internal Radiation Therapy" (known as SIRT). Radiation is an effective treatment for destroying tumors. It is widely used in cancer treatment. However, radiation can harm normal tissue. SIR-Spheres are tiny plastic beads. They contain a radioactive agent called Yttrium-90. These beads can be delivered through a small tube inserted into the blood vessel that goes directly to the tumor. The radiation goes directly to the tumor. This spares healthy parts of your liver.

研究概览

研究类型

介入性

注册 (实际的)

32

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New York
      • New York、New York、美国、10065
        • Memorial Sloan-Kettering Cancer Center 1275 York Avenue

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Histologic confirmation of colorectal cancer.
  • Unequivocal imaging of hepatic metastases.
  • Dominant Liver metastases. (Small amount extrahepatic disease allowed.)
  • Unresectable liver metastases.
  • Liver Metastases non-eligible for, or progressed after ablation
  • Failed prior HAC.
  • ECOG performance status 0 - 1
  • WBC > or = to 1.5 x 109/L
  • Platelets > or = to 50 x 109/L
  • Creatinine ≤ 1.5 mg/dl
  • Bilirubin ≤ 1.5 mg/dl
  • Age > or = to 18 years
  • Female patients must either be postmenopausal, sterile (surgically or radiation- or chemically-induced), or if sexually active, must agree to use an acceptable method of contraception.
  • Male patients must be surgically sterile, or if sexually active, must agree to use an acceptable method of contraception.
  • Life expectancy of at least 3 months without any active treatment.
  • No chemotherapy regimen administration for at least 4 weeks prior to SIRT administration

Exclusion Criteria:

  • Evidence of severe cirrhosis (CHILDS B and C), portal hypertension with gastroesophageal varices and liver failure as determined by clinical, radiologic or laboratory assessment.
  • Previous radiotherapy delivered to the liver.
  • Pregnant or breast-feeding.
  • Any of the following are contraindications to the use of Yttrium-90 microspheres, and are therefore exclusion criteria:

    • With a Tc-99m macroaggregated albumin (MAA) hepatic arterial perfusion scintigraphy that shows any disposition to the gastrointestinal tract that cannot be corrected by angiographic and embolization techniques.
    • With more than 20% shunting of blood to the lungs as estimated in the Lung Scintigram performed after the intraarterial injection of Tc MAA. Radiation pneumonitis has been seen in patients receiving doses of Yttrium-90 greater than 30 Gy in a single treatment. This corresponds to the shunt over 20% presence of vascular abnormalities, bleeding diathesis, making catheterization of the hepatic artery contraindication.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Unresectable colon cancer patients with liver metastases
This study will be performed to evaluate the safety of Selective Internal Radiation Therapy (SIRT) in patients with liver only colorectal cancer metastases that have received hepatic arterial infusion pump and have progressed through at least one line of chemotherapy.
SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
To determine the safety, toxicity, and maximum tolerated dose of SIR-Spheres® in patients with unresectable metastatic colorectal cancer to the liver (CLM) who have received previous hepatic arterial infusion chemotherapy (HAC).
大体时间:2 years
2 years

次要结果测量

结果测量
大体时间
To obtain preliminary evidence of any clinical efficacy of the SIRT therapy in these heavily pretreated patients with unresectable CLM who have received hepatic arterial infusion pump and have failed at least one line of prior chemotherapy.
大体时间:2 years
2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年8月1日

初级完成 (实际的)

2014年12月1日

研究完成 (实际的)

2014年12月1日

研究注册日期

首次提交

2009年9月3日

首先提交符合 QC 标准的

2009年9月3日

首次发布 (估计)

2009年9月4日

研究记录更新

最后更新发布 (估计)

2014年12月11日

上次提交的符合 QC 标准的更新

2014年12月10日

最后验证

2014年12月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

SIR-spheres® (Selective Internal Radiation Therapy)的临床试验

3
订阅